TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 18.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 518 shares of the company’s stock after selling 119 shares during the quarter. Fred Alger Management LLC’s holdings in TransMedics Group were worth $78,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMDX. International Assets Investment Management LLC purchased a new stake in TransMedics Group during the second quarter worth approximately $47,000. J.Safra Asset Management Corp boosted its position in TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC boosted its position in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the period. Fidelis Capital Partners LLC purchased a new position in TransMedics Group in the first quarter valued at about $35,000. Finally, Amalgamated Bank raised its position in TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after purchasing an additional 70 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $159.14 on Friday. The company has a debt-to-equity ratio of 2.67, a quick ratio of 8.48 and a current ratio of 9.37. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $177.37. The company has a 50-day moving average of $156.02 and a 200-day moving average of $130.87. The company has a market capitalization of $5.24 billion, a P/E ratio of -468.06 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.03) earnings per share. Equities analysts expect that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TMDX. Needham & Company LLC began coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 target price for the company. Piper Sandler lifted their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Oppenheimer upped their target price on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research note on Thursday, June 6th. They set an “overweight” rating and a $161.00 price target on the stock. Finally, Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $174.30.

Insider Buying and Selling

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total value of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,948,714.31. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock worth $9,650,880 over the last ninety days. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.